
TRVI Stock Forecast & Price Target
TRVI Analyst Ratings
Bulls say
Trevi Therapeutics has demonstrated a strengthened financial position with a cash balance of $194.9 million, projected to sustain operations through 2028, which positions the company favorably for its late-stage development plans. The company's operational advancements, particularly in progressing Haduvio towards Phase 3 trials for chronic cough indications, reflect meaningful upside potential in an underserved market, with forecasts estimating a $1.5 billion sales opportunity for the drug in idiopathic pulmonary fibrosis alone. Additionally, the narrowing of the net loss to $11.8 million from $13.2 million the previous year underscores improved financial efficiency as clinical momentum continues to build.
Bears say
Trevi Therapeutics Inc. has reported a significant decrease in research and development (R&D) expenses to $10.1 million for Q3, attributed to the winding down of previous clinical trials. The company faces multiple risks including potential delays in the development of its lead product Haduvio, competitive challenges from other therapeutics, and the possibility of losing market exclusivity or facing regulatory hurdles. Additionally, there is an anticipated need for capital raising before reaching profitability, which presents further financial uncertainty and could exacerbate share price volatility.
This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRVI Analyst Forecast & Price Prediction
Start investing in TRVI
Order type
Buy in
Order amount
Est. shares
0 shares